Frequently Asked Questions for Providers
Where can I resolve questions about providing PrEP?
The Clinician Consultation Center at UCSF provides clinicians of all experience levels prompt, expert responses to questions about managing HIV/AIDS, perinatal HIV, pre-exposure prophylaxis, and bloodborne pathogen exposures.
You can call a clinician during business hours or review their collection of clinical resources at any hour.
Check out the CCC here
Is Truvada or Descovy the best option for PrEP?
Both Truvada (TDF/FTC) and Descovy (TAF/FTC) are safe and appropriate options for PrEP, although the former has robust evidence in multiple populations beyond cisgender men who have sex with men and transgender women. TAF/FTC has not been shown to be more effective than TDF/FTC. Study findings show that TAF/FTC is “noninferior” to TDF/FTC in preventing HIV—meaning that TAF/FTC is not better but, rather, similarly as effective as TDF/FTC.
The New York City Department of Health and Mental Hygiene
released a guidance affirming TDF/FTC remains the first-line regimen for PrEP. More information on the pros and cons of these regimens are summarized in this
recent letter in the Annals of Internal Medicine.
How can Granite State PrEP Connect support my PrEP practice?
Our navigator or network of PrEP advocates can work with you and your patients to address issues from adherence to accessing assistance programs.
Provides are also invited to reach out via call, text, or email to request:
- Provider trainings
- PrEP implementation information
- Promotional and educational materials
How should I talk to patients about Granite State PrEP Connect?
If you feel a patient is at-risk for HIV and could benefit from peer support, we recommend you have them send a text or email to our navigator during their visit.
Our navigator can work with them to resolve questions about access, promote adherence, and answer questions they might feel more comfortable asking in a non-clinical setting. All services provided are free and confidential.
When will injectable PrEP be an option for my patients?
Interim results from HIV Prevention Trials Network (HPTN) 083 study showed injectable cabotegravir every 2 months was more effective at preventing HIV than currently oral PrEP options. Similar to recent TAF/FTC trials, we are lacking data on cisgender women and people who inject drugs.
The FDA has not yet approved injectable cabotegravir for PrEP
as Canada has. We will share updates as they become available and welcome additional options for people seeking to lower their risk of contracting HIV.